The effectiveness of the CD133 bispecific antibody has been studied in colorectal cancer and glioblastoma stem cells [22, 23]; however, the study of T cells secreting engager molecules in CCA has not yet been reported. The gene discussed is PROM1; the disease is cholangiocarcinoma.